<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01834742</url>
  </required_header>
  <id_info>
    <org_study_id>NER1006-01/2011 (OUT)</org_study_id>
    <nct_id>NCT01834742</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects</brief_title>
  <acronym>OUT</acronym>
  <official_title>Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierrel Research Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effect of various modified low volume polyethylene glycol&#xD;
      (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool&#xD;
      output in healthy subjects. In addition, the study is to assess and compare the safety and&#xD;
      tolerance of the modified PEG+ASC formulations following oral administration with the safety&#xD;
      profile of MOVIPREPÂ®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Variable</measure>
    <time_frame>36 Hours</time_frame>
    <description>Stool weight output generated from the start of intake for the following 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PEG3350 concentration</measure>
    <time_frame>96 Hours</time_frame>
    <description>Concentration of PEG3350 in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sulphate concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of PEG3350 in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascorbic acid concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of ascorbic acid in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of electrolytes in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>96 hours</time_frame>
    <description>Spontaneouly reported adverse events will be recorded throughout the study</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Part A, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 1 plus fixed morning dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 2 plus fixed morninf does</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 3 plus fixed morning dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moviprep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus alternative morning dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moviprep</intervention_name>
    <description>Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.</description>
    <arm_group_label>Part A, arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.</description>
    <arm_group_label>Part B, arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.</description>
    <arm_group_label>Part B, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.</description>
    <arm_group_label>Part B, arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.</description>
    <arm_group_label>Part B, arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject's written informed consent must be obtained prior to inclusion.&#xD;
&#xD;
          2. Healthy subjects with an age of 18 to 45 years.&#xD;
&#xD;
          3. Healthy subjects need to be without any history of clinical significant&#xD;
             gastrointestinal symptoms by clinical judgement and without the presence of acute&#xD;
             abdominal discomfort or symptoms.&#xD;
&#xD;
          4. Females must be surgically sterile, practicing true sexual abstinence or using an&#xD;
             acceptable form of effective contraception throughout the study from the following&#xD;
             list: contraceptive implants, injectables, oral contraceptives, intrauterine system&#xD;
             (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method&#xD;
             (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository. Hormonal&#xD;
             and IUD methods of contraception must be established for a period of 3 months prior to&#xD;
             dosing and cannot be changed or altered during the study. All females must have a&#xD;
             negative pregnancy test at screening and check-in.&#xD;
&#xD;
          5. Willing, able and competent to complete the entire procedure and to comply with study&#xD;
             instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of laxatives in the last 12 months or colon motility altering drugs in the last 6&#xD;
             months.&#xD;
&#xD;
          2. Use of any prescription or over-the-counter (OTC) medication within 4 weeks prior to&#xD;
             the first dose of investigational drug (excluding hormonal contraception, and&#xD;
             occasional use of nonsteroidal anti-inflammatory drugs [NSAID], acetaminophen or&#xD;
             metamizole).&#xD;
&#xD;
          3. Donation or loss of 500 mL or more of blood within 8 weeks prior to the first dose of&#xD;
             investigational drug.&#xD;
&#xD;
          4. Any evidence of the history or presence of organic or functional gastrointestinal&#xD;
             conditions (e.g. chronic constipation, irritable bowel syndrome [IBS], inflammatory&#xD;
             bowel disease [IBD]).&#xD;
&#xD;
          5. Exhibiting relevant abnormal gastrointestinal motility according to clinical judgement&#xD;
             in the past or now.&#xD;
&#xD;
          6. History or presence of any clinically significant acute illness within the 4 weeks&#xD;
             prior to the first dose of investigational drug based on clinical judgement at&#xD;
             screening and check-in evaluation.&#xD;
&#xD;
          7. Known glucose-6-phosphatase dehydrogenase deficiency.&#xD;
&#xD;
          8. Known phenylketonuria.&#xD;
&#xD;
          9. History or evidence of any clinical significant systemic cardiovascular, hepatic,&#xD;
             pulmonal, neurological, metabolic and/or renal organ dysfunction.&#xD;
&#xD;
         10. History of clinically significant drug allergy; history of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis), known hypersensitivity to polyethylene glycols&#xD;
             and/or ascorbic acid.&#xD;
&#xD;
         11. History or evidence of any clinically relevant electrocardiogram (ECG) abnormalities&#xD;
             and hypertension.&#xD;
&#xD;
         12. Evidence of dehydration.&#xD;
&#xD;
         13. Any evidence for abnormal sodium or potassium levels or clinically significant other&#xD;
             electrolyte disturbances.&#xD;
&#xD;
         14. Females who are pregnant, having a positive pregnancy test at screening and/or&#xD;
             admission to unit or planning a pregnancy. Females not using reliable methods of birth&#xD;
             control.&#xD;
&#xD;
         15. Clinically relevant findings on physical examination based on Investigator's&#xD;
             judgement.&#xD;
&#xD;
         16. Clinically relevant deviations of laboratory parameters from reference ranges at&#xD;
             screening or check-in evaluation.&#xD;
&#xD;
         17. Positive serology for chronic viral hepatitis or human immunodeficiency virus (HIV) at&#xD;
             screening.&#xD;
&#xD;
         18. History of drug or alcohol abuse within the 12 months prior to dosing or evidence of&#xD;
             such abuse as indicated by the laboratory assays conducted during the screening or&#xD;
             check-in evaluations.&#xD;
&#xD;
         19. Subjects who are unwilling to comply with the provisions of the study protocol.&#xD;
&#xD;
         20. Concurrent participation in an investigational drug study or participation within 3&#xD;
             month of study entry.&#xD;
&#xD;
         21. Subject has a condition or is in a situation, which in the Investigators opinion may&#xD;
             put the subject at significant risk, may confound the study results, or may interfere&#xD;
             significantly.&#xD;
&#xD;
         22. Previous participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Cinca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pierrel Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pierrel Research HP-RO-SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300244</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Research HP-RO-SRL</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moviprep</keyword>
  <keyword>PEG3350</keyword>
  <keyword>Laxative</keyword>
  <keyword>Stool Output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

